June 2, 2017 10:49 AM EDT
Bioregnum
Opinion

Thumbs up: Can­cer drug R&D is ex­plod­ing, get ready for the pric­ing de­bate to fol­low

I ar­rived in Chica­go last night, still try­ing to sort out how to pri­or­i­tize the news com­ing out of AS­CO this week­end. In the lead …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Re­searchers make case against Gilead in HIV prod­uct hop­ping fight

Viking Ther­a­peu­tics taps Cor­den­Phar­ma to man­u­fac­ture its obe­si­ty drugs

Mallinck­rodt and En­do ex­plor­ing a $7B merg­er — re­port

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times